Table 2 Demographics of patients with missense mutations in SETD2

12

32

M

Right frontal lobe

Recurrent/residual high grade glioma, IDH-mutant

IV

p.G1659D (4%)

p.S1268F (3%)

IDH1 p.R132H (49%)

CDKN2A p.A36Rfs*17 (72%)

NOTCH1 p.? (3%)

TP53 p.? (84%)

EP300 p.Q2224* (2%)

History of anaplastic astrocytoma resected in 2011 and 2012 status-post resection and chemoradiation

72^c

13

69

M

Right frontal lobe

Anaplastic astrocytoma, IDH-wildtype, WHO grade III

III

p.I1398T (49%)^b

EGFR p.G598V (94%)

EGFR amplification

KMT2C p.S777Kfs*19 (24%)

None

13^d

14

60

M

Left frontal lobe

Recurrent/residual glioblastoma, IDH-wildtype

IV

p.A2458T (32%)

p.S1088F (9%)

MSH6 p.F1088Lfs*5 (9%)

TET2 p.W1847* (14%)

EZH2 p.? (10%)

PTCH1 p.Y1316Tfs*56 (6%)

PTEN p.? (4%)

TP53 p.H179Y (3%), p.P152L (49%), p.S127F (8%)

NF1 p.? (9%), p.W2229* (6%)

KDM6A p.? (9%)

History of glioblastoma resected 2013 and 2015 status-post chemoradiation

44^e

15

64

M

Right frontal lobe

Anaplastic astrocytoma, IDH-wildtype, WHO grade III

III

p.A2242V (49%)^b

EGFR p.A289T (32%)

PTEN p.E7Rfs*17 (18%), p.R130del (7%)

None

2^c

16

27

F

Right frontal

Recurrent/residual glioblastoma, IDH-mutant

IV

p.E1692K (7%)

p.R385K (2%)

IDH1 p.R132H (38%)

KMT2C p.? (3%)

MEN1 p.? (2%)

ARID2 p.Q1604* (2%)

BRCA2 p.Q2009* (23%)

TP53 p.Y220Pfs*28 (90%)

History of glioblastoma resected 2013 and 2015 status-post chemoradiation

49^f

17

42

M

Superior saggital sinus, extra axial

Recurrent/residual atypical meningioma

III

p.G1014D (22%)

BRCA2 p.R2494* (3%)

History of atypical meningioma resected 2009 status-post radiation

96^c

18

33

M

4th ventricle

Choroid plexus papilloma, WHO grade I

I

p.R1089Q (51%)^b

None

None

5^c

19

18

M

Cerebellum, left hemisphere

Medulloblastoma, nodular desmoplastic variant, SHH subgroup, WHO grade IV

IV

p.V2371L (5%)

p.T1663M (6%)

ATM p.L1327* (42%)

CTCF p.R448* (7%)

PTCH1 p.C454* (41%)

TERT p.? (57%)

None

40^d